Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis

BMC Psychiatry

Volumn 9, Issue , 2009, Pages

  Stauffer, Virginia L ^a   Lipkovich, Ilya ^b   Hoffmann, Vicki Poole ^b   Heinloth, Alexandra N ^c   Scott, H Scott ^a   Kinon, Bruce J ^b  

^a Lilly USA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UnitedHealth Group Alliances   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; NIZATIDINE; OLANZAPINE; PLACEBO; SIBUTRAMINE; BENZODIAZEPINE DERIVATIVE; CYCLOBUTANE DERIVATIVE;

APPETITE; ARTICLE; BIPOLAR DISORDER; BODY MASS; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; FEEDING BEHAVIOR; HUMAN; HUNGER; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; OVERNUTRITION; PATIENT COUNSELING; POST HOC ANALYSIS; PSYCHOEDUCATION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; VISUAL ANALOG SCALE; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; ADULT; COGNITIVE DEFECT; DRUG COMBINATION; DRUG EFFECT; FEMALE; MALE;

ADULT; AMANTADINE; APPETITE; BENZODIAZEPINES; BIPOLAR DISORDER; COGNITION DISORDERS; CYCLOBUTANES; DRUG THERAPY, COMBINATION; FEEDING BEHAVIOR; FEMALE; HUMANS; MALE; NIZATIDINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; WEIGHT GAIN; WEIGHT LOSS;

EID: 65249137644     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-9-12     Document Type: Article

References (42)

1. Barnett AH Mackin P Chaudhry I Farooqi A Gadsby R Heald A Hill J Millar H Peveler R Rees A Singh V Taylor D Vora J Jones PB Minimising metabolic and cardiovascular risk in schizophrenia: Diabetes, obesity and dyslipidaemia J Psychopharmacol 2007, 21:357-373 10.1177/ 0269881107075509 17656425
2. Allison DB Mentore JL Heo M Chandler LP Cappelleri JC Infante MC Weiden PJ Antipsychotic-induced weight gain: A comprehensive research synthesis Am J Psychiatry 1999, 156:1686-1696 10553730
3. Eli Lilly and Company Zyprexa (Olanzapine) [package insert] Eli Lilly and Company, Indianapolis, IN 2007
4. Ogden CL Yanovski SZ Carroll MD Flegal KM The epidemiology of obesity Gastroenterology 2007, 132:2087-2102 10.1053/j.gastro.2007.03.052 17498505
5. Newcomer JW Medical risk in patients with bipolar disorder and schizophrenia J Clin Psychiatry 2006, 67:e16 17201046
6. Lieberman JA Stroup TS McEvoy JP Swartz MS Rosenheck RA Perkins DO Keefe RS Davis SM Davis CE Lebowitz BD Severe J Hsiao JK Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 2005, 353:1209-1223 10.1056/NEJMoa051688 16172203
7. Deberdt W Lipkovich I Poole Hoffman V Stauffer VL Edwards SE Hardy T Kollack-Walker S The Comparison of Efficacy and Safety of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients with Schizophrenia or Schizoaffective Disorder [abstract] Biol Psychiatry 2007, 61:258S
8. Ganguli R Behavioral Therapy for Weight Loss in Patients with Schizophrenia J Clin Psychiatry 2007, 68:19-25 17539696
9. Faulkner G Cohn T Remington G Interventions to reduce weight gain in schizophrenia Cochrane Database Syst Rev 2007, CD005148 17253540
10. Baptista T Elfakih Y Uzcategui E Sandia I Talamo E raujo de BE Beaulieu S Pharmacological management of atypical antipsychotic-induced weight gain CNS Drugs 2008, 22:477-495 10.2165/00023210-200822060-00003 18484791
11. Assuncao SS Ruschel SI Rosa LC Campos JA Alves MJ Bracco OL de Lima MS Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine Rev Bras Psiquiatr 2006, 28:270-276 17242805
12. Bahk WM Lee KU Chae JH Pae CU Jun T Kim KS Open label study of the effect of amantadine on weight gain induced by olanzapine Psychiatry Clin Neurosci 2004, 58:163-167 10.1111/j.1440-1819.2003.01211.x 15009821
13. Deberdt W Winokur A Cavazzoni PA Trzaskoma QN Carlson CD Bymaster FP Wiener K Floris M Breier A Amantadine for weight gain associated with olanzapine treatment Eur Neuropsychopharmacol 2005, 15:13-21 10.1016/ j.euroneuro.2004.03.005 15572269
14. Cavazzoni P Tanaka Y Roychowdhury SM Breier A Allison DB Nizatidine for prevention of weight gain with olanzapine: A double-blind placebo-controlled trial Eur Neuropsychopharmacol 2003, 13:81-85 10.1016/ S0924-977X(02)00127-X 12650950
15. Stunkard AJ Messick S The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger J Psychosom Res 1985, 29:71-83 10.1016/0022-3999(85)90010-8 3981480
16. Khazaal Y Fresard E Zimmermann G Trombert NM Pomini V Grasset F Borgeat F Zullino D Eating and weight related cognitions in people with Schizophrenia: A case control study Clin Pract Epidemol Ment Health 2006, 2:29 1634745 17076886 10.1186/1745-0179-2-29
17. Khazaal Y Fresard E Rabia S Chatton A Rothen S Pomini V Grasset F Borgeat F Zullino D Cognitive behavioural therapy for weight gain associated with antipsychotic drugs Schizophr Res 2007, 91:169-177 10.1016/j.schres.2006.12.025 17306507
18. Lipkovich I Citrome L Perlis R Deberdt W Houston JP Ahl J Hardy T Early predictors of substantial weight gain in bipolar patients treated with olanzapine J Clin Psychopharmacol 2006, 26:316-320 10.1097/ 01.jcp.0000219916.88810.1c 16702898
19. Lipkovich I Jacobson JG Hardy TA Hoffmann VP Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder BMC Psychiatry 2008, 8:78 2566555 18793440 10.1186/1471-244X-8-78
20. Basson BR Kinon BJ Taylor CC Szymanski KA Gilmore JA Tollefson GD Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone J Clin Psychiatry 2001, 62:231-238 11379836
21. Saddichha S Ameen S Akhtar S Predictors of antipsychotic-induced weight gain in first-episode psychosis: Conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol J Clin Psychopharmacol 2008, 28:27-31 10.1097/ jcp.0b013e3181602fe6 18204337
22. Kinon BJ Kaiser CJ Ahmed S Rotelli MD Kollack-Walker S Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders J Clin Psychopharmacol 2005, 25:255-258 10.1097/ 01.jcp.0000161501.65890.22 15876905
23. Atmaca M Kuloglu M Tezcan E Ustundag B Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain Hum Psychopharmacol 2003, 18:457-461 10.1002/hup.514 12923824
24. Hester EK Thrower MR Current options in the management of olanzapine-associated weight gain Ann Pharmacother 2005, 39:302-310 10.1345/aph.1D423 15632224
25. Milano W Grillo F Del MA De RM Sanseverino B Petrella C Capasso A Appropriate intervention strategies for weight gain induced by olanzapine: A randomized controlled study Adv Ther 2007, 24:123-134 10.1007/BF02850000 17526469
26. Graham KA Gu H Lieberman JA Harp JB Perkins DO Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine Am J Psychiatry 2005, 162:1744-1746 10.1176/appi.ajp.162.9.1744 16135638
27. Kim JH Yim SJ Nam JH A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia Schizophr Res 2006, 82:115-117 10.1016/ j.schres.2005.10.001 16326074
28. Poyurovsky M Isaacs I Fuchs C Schneidman M Faragian S Weizman R Weizman A Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: A double-blind, placebo-controlled study Am J Psychiatry 2003, 160:297-302 10.1176/appi.ajp.160.2.297 12562576
29. Poyurovsky M Fuchs C Pashinian A Levi A Faragian S Maayan R Gil-Ad I Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: A double-blind placebo-controlled study Psychopharmacology (Berl) 2007, 192:441-448 10.1007/s00213-007-0731-1 17310385
30. Wu RR Zhao JP Guo XF He YQ Fang MS Guo WB Chen JD Li LH Metformin Addition Attenuates Olanzapine-Induced Weight Gain in Drug-Naive First-Episode Schizophrenia Patients: A Double-Blind, Placebo-Controlled Study Am J Psychiatry 2008, AiA:1-7
31. Baptista T Rangel N Fernandez V Carrizo E El FY Uzcategui E Galeazzi T Gutierrez MA Servigna M Davila A Uzcategui M Serrano A Connell L Beaulieu S de Baptista EA Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: A multicentric, double-blind, placebo-controlled trial Schizophr Res 2007, 93:99-108 10.1016/j.schres.2007.03.029 17490862
32. Floris M Lejeune J Deberdt W Effect of amantadine on weight gain during olanzapine treatment Eur Neuropsychopharmacol 2001, 11:181-182 10.1016/ S0924-977X(01)00072-4 11313165
33. Gordon A Price LH Mood stabilization and weight loss with topiramate Am J Psychiatry 1999, 156:968-969 10360144
34. Levy E Margolese HC Chouinard G Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia J Clin Psychiatry 2002, 63:1045 12469686
35. Littrell KH Petty RG Hiligoss NM Peabody CD Johnson CG Weight loss with topiramate Ann Pharmacother 2001, 35:1141-1142 10.1345/aph.10414 11573869
36. Morrison JA Cottingham EM Barton BA Metformin for weight loss in pediatric patients taking psychotropic drugs Am J Psychiatry 2002, 159:655-657 10.1176/appi.ajp.159.4.655 11925306
37. Nickel MK Nickel C Muehlbacher M Leiberich PK Kaplan P Lahmann C Tritt K Krawczyk J Kettler C Egger C Rother WK Loew TH Influence of topiramate on olanzapine-related adiposity in women: A random, double-blind, placebo-controlled study J Clin Psychopharmacol 2005, 25:211-217 10.1097/ 01.jcp.0000162806.46453.38 15876898
38. Pae CU Kim JJ Lee KU Lee CU Bahk WM Lee SJ Lee C Paik IH Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: A pilot study Hum Psychopharmacol 2003, 18:453-456 10.1002/hup.507 12923823
39. Sacchetti E Guarneri L Bravi D H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients Biol Psychiatry 2000, 48:167-168 10.1016/S0006-3223(00)00872-6 10903413
40. Henderson DC Copeland PM Daley TB Borba CP Cather C Nguyen DD Louie PM Evins AE Freudenreich O Hayden D Goff DC A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain Am J Psychiatry 2005, 162:954-962 10.1176/appi.ajp.162.5.954 15863798
41. Wu RR Zhao JP Jin H Shao P Fang MS Guo XF He YQ Liu YJ Chen JD Li LH Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: A randomized controlled trial JAMA 2008, 299:185-193 10.1001/jama.2007.56-b 18182600
42. Kinon BJ Basson BR Gilmore JA Tollefson GD Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia J Clin Psychiatry 2001, 62:92-100 11247108